Cargando…

Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer

BACKGROUND: Ovarian cancer remains the most fatal gynecological malignancy. Current therapeutic options are limited due to late diagnosis in the majority of the cases, metastatic spread to the peritoneal cavity and the onset of chemo-resistance. Thus, novel therapeutic approaches are required. Stati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Göbel, Andy, Zinna, Valentina M., Dell’Endice, Stefania, Jaschke, Nikolai, Kuhlmann, Jan Dominik, Wimberger, Pauline, Rachner, Tilman D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388525/ https://www.ncbi.nlm.nih.gov/pubmed/32727400 http://dx.doi.org/10.1186/s12885-020-07164-x

Ejemplares similares

The Role of Inflammation in Breast and Prostate Cancer Metastasis to Bone
por: Göbel, Andy, et al.
Publicado: (2021)

Plasma levels of Semaphorin 4D are decreased by adjuvant tamoxifen but not aromatase inhibitor therapy in breast cancer patients
por: Göbel, Andy, et al.
Publicado: (2019)

Clinical impact of soluble Neuropilin-1 in ovarian cancer patients and its association with its circulating ligands of the HGF/c-MET axis
por: Klotz, Daniel Martin, et al.
Publicado: (2022)

Regulation of VEGF by mevalonate pathway inhibition in breast cancer
por: Rachner, Tilman D., et al.
Publicado: (2013)

Dickkopf-1 is regulated by the mevalonate pathway in breast cancer
por: Rachner, Tilman D, et al.
Publicado: (2014)

Prognostic relevance of longitudinal HGF levels in serum of patients with ovarian cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

The levels of soluble cMET ectodomain in the blood of patients with ovarian cancer are an independent prognostic biomarker
por: Klotz, Daniel Martin, et al.
Publicado: (2021)

Skeletal endocrinology: where evolutionary advantage meets disease
por: Jaschke, Nikolai, et al.
Publicado: (2021)

Prospects of adjuvant RANKL inhibition in breast cancer?
por: Rachner, T D, et al.
Publicado: (2015)

LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival
por: Kuhlmann, Jan Dominik, et al.
Publicado: (2012)

EMT-like circulating tumor cells in ovarian cancer patients are enriched by platinum-based chemotherapy
por: Chebouti, Issam, et al.
Publicado: (2017)

Targeting syndecan-1 in breast cancer inhibits osteoclast functions through up-regulation of osteoprotegerin
por: Benad-Mehner, Peggy, et al.
Publicado: (2013)

Inhibition of the mevalonate pathway augments the activity of pitavastatin against ovarian cancer cells
por: Abdullah, Marwan Ibrahim, et al.
Publicado: (2017)

Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells
por: Göbel, Andy, et al.
Publicado: (2019)

Clinical relevance of circulating MACC1 and S100A4 transcripts for ovarian cancer
por: Link, Theresa, et al.
Publicado: (2019)

Inhibition of the mevalonate pathway improves myocardial fibrosis
por: Xu, Huifeng, et al.
Publicado: (2021)

ERCC1-expressing circulating tumor cells as a potential diagnostic tool for monitoring response to platinum-based chemotherapy and for predicting post-therapeutic outcome of ovarian cancer
por: Chebouti, Issam, et al.
Publicado: (2016)

The conjugated antimetabolite 5-FdU-ECyd and its cellular and molecular effects on platinum-sensitive vs. -resistant ovarian cancer cells in vitro
por: Schott, Sarah, et al.
Publicado: (2017)

Decoding Single Cell Morphology in Osteotropic Breast Cancer Cells for Dissecting Their Migratory, Molecular and Biophysical Heterogeneity
por: Bemmerlein, Lila, et al.
Publicado: (2022)

Zoledronic acid and atorvastatin inhibit αvβ3-mediated adhesion of breast cancer cells
por: Wilke, Maria, et al.
Publicado: (2014)

Mevalonate kinase deficiencies: from mevalonic aciduria to hyperimmunoglobulinemia D syndrome
por: Haas, Dorothea, et al.
Publicado: (2006)

Drug repositioning of mevalonate pathway inhibitors as antitumor agents for ovarian cancer
por: Kobayashi, Yusuke, et al.
Publicado: (2017)

Diagnostic value of urinary mevalonic acid excretion in mevalonate kinase deficiency (MKD)
por: Jeyaratnam, Jerold, et al.
Publicado: (2014)

Establishment and Molecular Characterization of an In Vitro Model for PARPi-Resistant Ovarian Cancer
por: Klotz, Daniel Martin, et al.
Publicado: (2023)

Diagnostic Benefit of the Detection of Mitotic Figures in Endometriotic Lesions
por: Wetzk, Michelle, et al.
Publicado: (2022)

Correction: Diagnostic Benefit of the Detection of Mitotic Figures in Endometriotic Lesions
por: Wetzk, Michelle, et al.
Publicado: (2023)

Inhibition of the mevalonate pathway affects epigenetic regulation in cancer cells
por: Karlic, Heidrun, et al.
Publicado: (2015)

Artesunate inhibits the mevalonate pathway and promotes glioma cell senescence
por: Wei, Shupei, et al.
Publicado: (2019)

Mesenchymal stromal cell-associated migrasomes: a new source of chemoattractant for cells of hematopoietic origin
por: Deniz, Ilker A., et al.
Publicado: (2023)

Dickkopf1 fuels inflammatory cytokine responses
por: Jaschke, Nikolai P., et al.
Publicado: (2022)

The mevalonate pathway in C. Elegans
por: Rauthan, Manish, et al.
Publicado: (2011)

Mevalonate Metabolism in Immuno-Oncology
por: Gruenbacher, Georg, et al.
Publicado: (2017)

Mevalonate kinase somatic mosaicism and bigenic genotypes may explain heterogeneity in mevalonate kinase deficiency
por: Shinar, Y, et al.
Publicado: (2015)

Ovarian tumour growth is characterized by mevalonate pathway gene signature in an orthotopic, syngeneic model of epithelial ovarian cancer
por: Greenaway, James B., et al.
Publicado: (2016)

Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
por: Klotz, Daniel Martin, et al.
Publicado: (2020)

APEX - the Hyperspectral ESA Airborne Prism Experiment
por: Itten, Klaus I., et al.
Publicado: (2008)

FNTB Promoter Polymorphisms Are Independent Predictors of Survival in Patients with Triple Negative Breast Cancer
por: Bachmann, Hagen Sjard, et al.
Publicado: (2022)

Synthesis of Heterologous Mevalonic Acid Pathway Enzymes in Clostridium ljungdahlii for the Conversion of Fructose and of Syngas to Mevalonate and Isoprene
por: Diner, Bruce A., et al.
Publicado: (2017)

Genomic variations of the mevalonate pathway in porokeratosis
por: Zhang, Zhenghua, et al.
Publicado: (2015)

Tocilizumab for the Treatment of Mevalonate Kinase Deficiency
por: Rafiq, Nadia K., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0ombij3b7b3adl75fno26rjkt1